Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial-论文-万方医学网

首页> > Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial

Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial

导出原文传递

翻译打印收藏纠错

第一作者： McCartney, Amelia

作者： McCartney, Amelia ^[1] ; Bonechi, Martina ^[2] ; De Luca, Francesca ^[3] ; Biagioni, Chiara ^[4] ; Curigliano, Giuseppe ; Moretti, Erica ; Minisini, Alessandro Marco ; Bergqvist, Mattias ; Benelli, Matteo ; Migliaccio, Ilenia ; Galardi, Francesca ; Risi, Emanuela ; De Santo, Irene ; Romagnoli, Dario ; Biganzoli, Laura ; Di Leo, Angelo ; Malorni, Luca

作者单位： Azienda USL Toscana Ctr,Hosp Prato ^[1] Ist Europeo Oncol,IRCCS ^[2] Dept Oncol,Azienda Sanitaria Univ Integrata Udine ^[3] Biov Int ^[4]

关键词 4/6 INHIBITOR RESISTANCE THERAPY FULVESTRANT COMBINATION ABEMACICLIB LETROZOLE

发布时间 2022-06-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial

相似文献

同项目论文

相关期刊

检索历史 清除

Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial

相似文献

同项目论文

相关期刊

检索历史清除